Compositions and methods for treating multiple myeloma
US-2017356917-A1 · Dec 14, 2017 · US
Pharmaceutical composition for treating or preventing Parkinson's disease comprising STT as an active ingredient
US11529334B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11529334-B2 |
| Application number | US-202016852182-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 17, 2020 |
| Priority date | Apr 19, 2019 |
| Publication date | Dec 20, 2022 |
| Grant date | Dec 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition comprising a STT compound as an active ingredient for the prevention or treatment of Parkinson's disease. STT showed neuroprotective effect and apoptosis recovery effect in the Parkinson's disease cell model, restored the reduced motility in the MPTP animal model, and was shown to significantly protect dopamine cells, so it can be used for the prevention and treatment of Parkinson's disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating Parkinson's disease in a subject in need of treatment, the method comprising administering to the subject a composition comprising STT (2-(5-Methyl-4-oxo-2-thioxo-1,3-thiazolidin-3-yl) ethanesulfonic acid) as an active ingredient, thereby treating Parkinson's disease in the subject. 2. The method of claim 1 , wherein the STT interacts with a TPP domain of DUSP10. 3. The method of claim 1 , wherein the STT inhibits ROS production. 4. A method for treating Parkinson's disease in a subject in need of treatment, the method comprising administering to the subject a composition comprising a DUSP10 protein or a polynucleotide encoding the DUSP10 protein as an active ingredient, thereby treating Parkinson's disease in the subject.
Assignees
Inventors
Classifications
Neurological disorders, e.g. Alzheimer's disease · CPC title
Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title
having an effect on the health of the nervous system or on mental function · CPC title
for diseases caused by alterations of genetic material · CPC title
- A61P25/16Primary
Anti-Parkinson drugs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11529334B2 cover?
- The present invention relates to a pharmaceutical composition comprising a STT compound as an active ingredient for the prevention or treatment of Parkinson's disease. STT showed neuroprotective effect and apoptosis recovery effect in the Parkinson's disease cell model, restored the reduced motility in the MPTP animal model, and was shown to significantly protect dopamine cells, so it can be us…
- Who is the assignee on this patent?
- Gachon Univ Of Industry—Academic Cooperation Foundation, Gil Medical Ct, Univ—Industry Cooperation Group Of Kyung Hee Univ, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61P25/16. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).